Sisu Pharma Email Format
Biotechnology ResearchCalifornia, United States2-10 Employees
Sisu Pharma exploits cellular stress by directly targeting HSF1, the Master Regulator of the heat shock response. Our HSF1 targeting platform (HI-LiTe) is being developed to deliver selective HSF1 degraders for oncology and therapies for use in neurodegenerative conditions and infection, providing a unique approach to treating these devastating diseases.